Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Healthcare Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

Aduro Biotech to Host Research and Development Day in New York

GlobeNewswire March 15, 2017

Aduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Community

GlobeNewswire March 10, 2017

Aduro Biotech Announces Upcoming Data Presentations at the 2017 American Association for Cancer Research Annual Meeting

GlobeNewswire March 6, 2017

Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference

GlobeNewswire March 2, 2017

Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results

GlobeNewswire March 1, 2017

Aduro Biotech to Present at Two Investor Conferences in March

GlobeNewswire February 28, 2017

Aduro Biotech to Present at the Leerink Partners 6th Annual Global Healthcare Conference

GlobeNewswire February 10, 2017

Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board

GlobeNewswire January 26, 2017

Aduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology

GlobeNewswire January 19, 2017

Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer

GlobeNewswire January 9, 2017

Aduro Biotech to Present at the 35th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 27, 2016

Aduro Biotech Europe’s Hans van Eenennaam, Ph.D. and John Dulos, Ph.D. Honored with the Intellectual Property Owners Education Foundation’s 43rd Inventor of the Year Award for Contributions in the Discovery of KEYTRUDA® (pembrolizumab)

GlobeNewswire December 6, 2016

Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD

GlobeNewswire December 5, 2016

Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma

GlobeNewswire December 3, 2016

Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD Clinical Trials

GlobeNewswire November 21, 2016

Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial

GlobeNewswire November 12, 2016

Aduro Biotech’s Personalized LADD Therapy Featured in an Oral Presentation at SITC’s New Cancer Immunotherapy Agents in Development Program

GlobeNewswire November 9, 2016

Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100

GlobeNewswire November 7, 2016

Aduro Biotech Reports Third Quarter 2016 Financial Results

GlobeNewswire November 2, 2016

Aduro Biotech Reports Partial Clinical Hold to Pause Enrollment in LADD Trials

GlobeNewswire October 24, 2016